苦黄注射液与门冬氨酸钾镁治疗病毒性肝炎的系统评价

目的:系统评价苦黄注射液与门冬酸钾镁治疗病毒性肝炎的疗效及安全性。方法:计算机检索Cochrane图书馆、PubMed、EMBase、中国知网(CNKI)、维普(VIP)、中国生物医学文献数据库(CBM),纳入苦黄注射液与门冬酸钾镁比较治疗病毒性肝炎的随机对照试验(RCT),对纳入的RCT进行质量评价,用Rev Man5.0软件对数据进行Meta分析。结果:共纳入8项RCT,合计1242例患者。Meta分析结果显示,苦黄注射液治疗病毒性肝炎的总有效率明显优于门冬酸钾镁,2组比较差异有统计学意义[RR=1.34,95%C(I1.22,1.46),P<0.00001];2组不良反应发生率比较差异无统计学意义[RR=3.33,95%C(I0.16,69.75),P=0.44]。结论:苦黄注射液治疗病毒性肝炎的疗效优于门冬酸钾镁,但因为纳入研究文献质量较低,尚需高质量、大样本的随机对照试验加以验证。

Kuhuang Injection vs.Potassium Magnesium Aspartate in the Treatment of Viral Hepatitis:a Systematic Review

OBJECTIVE:To evaluate the efficacy and safety of Kuhuang injection vs.Potassium magnesium aspartate in the treatment of viral hepatitis.METHODS:Retrieved from Cochrane Library,PubMed,EMBase,CNKI,VIP,CBM,randomized controlled trails(RCT) included on Kuhuang injection vs.Potassium magnesium aspartate in the treatment of viral hepatitis were evaluated and analyzed by the Rev Man 5.0 software.RESULTS:8 studies involving 1 242 patients were included.The results of Meta-analysis demonstrated that Kuhuang injection was superior to Potassium magnesium aspartate in total effective rate,there was statistical significance [RR=1.34,95%CI(1.22,1.46),P<0.000 01].There was no statistically difference in incidence of ADR [RR=3.33,95%CI(0.16,69.75),P=0.44].CONCLUSIONS:Kuhuang injection is better than Potassium magnesium aspartate in the treatment of viral hepatitis.However,due to the limited quantity and quality of the included studies,high-quality large-scale RCT are required.